Previous 10 | Next 10 |
- Poster details the research into CYT-0851 mechanism of action and identification as an inhibitor of monocarboxylate transporter activity Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synt...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a ...
Gainers: Canoo ( GOEV ) +9% . Eargo ( EAR ) +5% . Weatherford International ( WFRD ) +5% . Tremor International ( TRMR ) +5% . Cyteir Therapeutics ( CYT ) +5% . Losers: Stronghold Digital Mining ( SDIG ) -6% . ...
The following slide deck was published by Cyteir Therapeutics, Inc. in conjunction with this event. For further details see: Cyteir Therapeutics (CYT) Investor Presentation - Slideshow
Cyteir Therapeutics press release ( NASDAQ: CYT ): Q2 GAAP EPS of -$0.34. Cash and cash equivalents as of June 30, 2022 were $166.4 million. For further details see: Cyteir Therapeutics GAAP EPS of -$0.34
- Sharpening focus on the pipeline extends cash runway into second half of 2024; Ended quarter with approximately $166 million in cash - IND submission for CYT-1853 postponed to focus on CYT-0851 and preclinical pipeline Cyteir Therapeutics, Inc. (“Cyteir”) (Na...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in th...
Gainers: Heart Core Enterprises (HTCR) +151%. MINISO Group Holding (MNSO) +33%. Imperial Petroleum (IMPP) +33%. Cyren (CYRN) +33%. One Connect Financial Technology (OCFT) +27%. SQL Technologies (SKYX) +27%. Rekor Systems (REKR) +27%. Rubius Therapeutics (RUBY) +24%. Bluejay Diagnostics (BJDX)...
- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a 44% disease control rate in the r...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentatio...
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
NASDAQ Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...